Anixa Biosciences (ANIX) EPS (Basic) (2011 - 2026)
Anixa Biosciences' (ANIX) quarterly EPS (Basic) came in at -$0.12 in Q2 2026, down 9.48% YoY from -$0.13 in Q2 2025, and up 100.0% on a QoQ basis from -$227302.5 in Q4 2025.
Anixa Biosciences (ANIX) EPS (Basic) (2011 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of EPS (Basic) data on file, last reported at -$0.12 in Q2 2026.
- Quarterly EPS (Basic) fell 9.48% year-over-year to -$0.12 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$219.94 (down 13186.63% YoY) and the FY2025 annual result came in at -$227558.4, down 257.75% from the prior year.
- EPS (Basic) grew to -$0.12 in Q2 2026, from -$227302.5 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.11 in Q2 2025 to a low of -$1.1 million in Q4 2023.
- A 5-year average of -$136387.9 and a median of -$156.78 in 2023 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) slumped 683188945.57% — and 2025, when it surged 99.97%.
- Tracing ANIX's EPS (Basic) over 5 years: stood at -$974699.7 in 2022, then fell by 14.27% to -$1.1 million in 2023, then jumped by 99.89% to -$1274.9 in 2024, then tumbled by 17729.38% to -$227302.5 in 2025, then jumped by 100.0% to -$0.12 in 2026.
- The last three EPS (Basic) figures came in at -$0.12 (Q2 2026), -$227302.5 (Q4 2025), and -$0.12 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | -0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -0.12 |
| Oct 31, 2025 | -227,302.46 |
| Jul 31, 2025 | -0.12 |
| Apr 30, 2025 | -0.11 |
| Jan 31, 2025 | -0.13 |
| Oct 31, 2024 | -1,274.88 |
| Jul 31, 2024 | -150.62 |
| Apr 30, 2024 | -117.88 |
| Jan 31, 2024 | -398.33 |
| Oct 31, 2023 | -1.11 Mn |
| Jul 31, 2023 | -156.78 |
| Apr 30, 2023 | -225.99 |
| Jan 31, 2023 | -299.73 |
| Oct 31, 2022 | -974,699.71 |
| Jul 31, 2022 | -192.08 |
| Apr 30, 2022 | -0.41 |
| Jan 31, 2022 | -0.43 |
| Oct 31, 2021 | -0.14 |
| Jul 31, 2021 | -0.31 |
| Apr 30, 2021 | -0.33 |